AstraZeneca Pharma India Limited

NSEI:ASTRAZEN Rapporto sulle azioni

Cap. di mercato: ₹187.9b

AstraZeneca Pharma India Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Sanjeev Panchal

Amministratore delegato

₹38.7m

Compenso totale

Percentuale dello stipendio del CEO83.4%
Mandato del CEO1.8yrs
Proprietà del CEOn/a
Durata media del management1.3yrs
Durata media del Consiglio di amministrazioneless than a year

Aggiornamenti recenti sulla gestione

Recent updates

AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Earnings Haven't Escaped The Attention Of Investors

Sep 18
AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Earnings Haven't Escaped The Attention Of Investors

We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability

Jun 03
We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability

Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S

May 22
Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S

We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease

Apr 04
We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease

Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

Nov 10
Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00

Jul 06
AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00

Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

Jun 16
Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)

Aug 02
Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)

Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock

Feb 25
Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock

Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?

Feb 04
Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?

Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

Jan 18
Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years

Dec 31
Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years

We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability

Dec 13
We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability

Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching

Nov 25
Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching

Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay

Nov 07
Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay

What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

Oct 20
What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Sep 24
AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today

Aug 28
If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today

What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?

Aug 02
What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?

Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?

Jul 12
Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Sanjeev Panchal rispetto agli utili di AstraZeneca Pharma India?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

₹959m

Mar 31 2024₹39m₹32m

₹2b

Dec 31 2023n/an/a

₹1b

Sep 30 2023n/an/a

₹2b

Jun 30 2023n/an/a

₹1b

Mar 31 2023₹21m₹5m

₹993m

Compensazione vs Mercato: La retribuzione totale di Sanjeev ($USD 459.01K ) è circa la media per le aziende di dimensioni simili nel mercato Indian ($USD 479.87K ).

Compensazione vs guadagni: La retribuzione di Sanjeev è aumentata di oltre il 20%, mentre gli utili aziendali sono diminuiti di oltre il 20% nell'ultimo anno.


AMMINISTRATORE DELEGATO

Sanjeev Panchal (47 yo)

1.8yrs

Mandato

₹38,725,314

Compensazione

Dr. Sanjeev Kumar Panchal serves as Country President of AstraZeneca Pharma India Limited since January 01, 2023 and serves as its Managing Director since January 01, 2023. He serves as Director of AstraZe...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Sanjeev Panchal
MD, Country President & Director1.8yrs₹38.73mNessun dato
Bhavana Agrawal
Whole-Time Director & CFO1.1yrs₹30.59mNessun dato
Pratap Bhuvanagiri
Legal Counsel7.8yrs₹3.73mNessun dato
Manasa R.
Company Secretary & Compliance Officer2.3yrsNessun datoNessun dato
Smita Saha
Vice President of Human Resourcesno data₹12.28mNessun dato
Ayush Agarwal
Interim Business Unit Head of Oncology & Director of Commercial Excellence1.3yrsNessun datoNessun dato
Praveen Akkinepally
Head of Oncology Business Unitless than a yearNessun datoNessun dato
Vinay Sharma
Business Unit Head - Rare Disease unitless than a yearNessun datoNessun dato
Pankaj Jain
Legal Headno dataNessun datoNessun dato

1.3yrs

Durata media

Gestione esperta: Il team dirigenziale di ASTRAZEN non è considerato esperto (durata media 1.3 anni), il che suggerisce un nuovo team.


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Sanjeev Panchal
MD, Country President & Director1.8yrs₹38.73mNessun dato
Bhavana Agrawal
Whole-Time Director & CFOless than a year₹30.59mNessun dato
Revathy Ashok
Independent Non-Executive Director7.9yrs₹1.20mNessun dato
Monica Widhani
Additional Independent Directorless than a yearNessun datoNessun dato
Hooi Chuah
Additional Non-Executive Directorless than a yearNessun datoNessun dato
Nirula Shilpa Divekar
Independent Non-Executive Chairperson of the Board2.9yrs₹1.30mNessun dato
Sylvia Lorena Ramon
Non-Executive Directorless than a yearNessun datoNessun dato

1.0yrs

Durata media

58yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di ASTRAZEN non è considerato esperto (durata media del mandato 1 anni), il che suggerisce un nuovo consiglio.